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Background: The role of ﬁnal kissing ballooning (FKB) after simple cross over
stenting in distal left main disease was not well evaluated.
Methods: Between February 2003 and December 2011, a total of 380 patients having
distal left main treated by simple stenting cross over left circumﬂex arterywere identiﬁed
from ASANMain registry. In patients treated with the simple cross over stenting, major
adverse cardiac events (MACE; the composite of death from any causes, myocardial
infarction (MI), or left main-target lesion revascularization (TLR)) were compared be-
tween those undergoing main vessel stenting only (No-FKB group, n¼277) or those
undergoing FKB after main vessel stenting (FKB group, n¼103) at 2 year follow-up.
Results: The 2-year incidence of MACE was similar between two groups (FKB:
12.1% vs. No-FKB: 7.9%, P¼0.29). In addition, death (FKB: 5.6% vs. No-FKB:
4.4%, P¼0.79), MI (FKB: 0% vs. No-FKB: 0.8%, P¼0.40), and left main TLR was
not signiﬁcantly different (FKB: 6.7% vs. No-FKB: 3.9%, P¼0.29). After adjustment,
the hazard ratio was 0.95 (0.33 – 2.69) (95% CI, P¼0.92) for the composite of death
or MI; 0.55 (0.20 – 1.51) (95% CI, P¼0.25) for left main TLR; 0.65 (0.31 – 1.36)
(95% CI, P¼0.25) for MACE.Table. Cumulative Incidence of Clinical Outcomes at 2 Years
FKB (N¼103) No-FKB (N¼277) P value
Death 5 (5.6%) 12 (4.4%) 0.79
Cardiac 2 (2.3%) 10 (3.7%) 0.43
Non-cardiac 1 (1.1%) 0 0.09
Unknown 2 (2.3%) 2 (0.8%) 0.28
Myocardial Infarction 0 2 (0.8%) 0.40
Death or Myocardial Infarction 5 (5.6%) 13 (4.8%) 0.91
Repeat Revascularization
Any 9 (10.0%) 18 (7.1%) 0.37
Target Vessel Revascularization 9 (10.0%) 16 (6.3%) 0.24
Target Lesion Revascularization
Left main-TLR* 6 (6.7%) 10 (3.9%) 0.29
MACEy 11 (12.1%) 21 (7.9%) 0.29
*Repeated revascularization for left main and proximal 5mm of left anterior descending ar-
tery or left circumﬂex artery
yThe composite of death from any causes, myocardial infarction, or left main-target lesion
revascularizationConclusions: In patients treated with the simple cross over stenting for distal left main
coronary artery bifurcation stenosis, FKB after main vessel stenting was not associated
with better clinical outcome compared with no FKB.Coronary Lesions - Long Lesions and Diffuse Disease
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Long-segment stenting (‡ 28 mm) with everolimus-eluting bioresorbable vascular
scaffolds in patients with coronary artery disease
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Background: Everolimus-eluting bioresorbable vascular scaffolds (BVS, Abbott
Vascular, Santa Clara, California, USA) are an upcoming technique in theJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Cointerventional treatment of coronary artery disease. It is known that the total length of
conventional metallic stents implanted is an independent predictor of stent thrombosis.
However, this has not been investigated in patients treated with a bioresorbable
vascular scaffold.
Methods: Long-segment stenting was deﬁned as a total scaffold length of at least
28 mm, regardless of the number of bioresorbable vascular scaffolds used. All
patients within the scope of our all-comers registry were included in this analysis.
Major adverse cardiac events (MACE) included target lesion revascularization
(TLR), cardiac death, myocardial infarction and emergency coronary bypass graft
surgery.
Results: A total of 119 patients were treated. Median age was 63 (55 – 70) years,
23.5% were female, 86.9% suffered from hypertension and 39.3% from diabetes.
Twenty percent underwent catheterization due to STEMI, 25.2% due to NSTEMI,
11.8% due to instable angina, 44.5% due to stable angina and in 0.8% another indi-
cation was present. Median procedure time was 64 (49 – 83) min, mean contrast
volume was 220.2 mL ( 99.2). In 3 cases the implantation of a BVS was not
possible. A total of 127 lesions were intervened with a total of 229 bioresorbable
vascular scaffolds (1.8 per lesion). Mean total scaffold length was 42.5  18.7 mm per
patient. 1.9  1.3 pre-dilatations per patient and in 61.2% post-dilatation were per-
formed. Median follow-up time was 179 (60 - 290) days. Two patients experienced a
scaffold thrombosis due to discontinuation of dual antiplatelet therapy and one patient
presented an in-scaffold restenosis. Total TLR and MACE rates were 2.6% and 5.2%,
respectively.
Conclusions: Given the dissolving character of bioresorbable vascular scaffolds they
might have a potential beneﬁt even in long lesions. Our ﬁndings demonstrate, that
long-segment stenting with bioresorbable vascular scaffolds is feasible and can be
performed with reasonable clinical mid-term outcome. However long-term data is
required.
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Background: The thin-strut, everolimus-eluting, platinum chromium PROMUS
Element stent (Boston Scientiﬁc, Natick, MA, USA) has shown favorable outcomes
up to 3 years post-implantation for the treatment of de novo long lesions or lesions in
small-caliber vessels, but longer-term follow-up has not been previously reported with
this stent in those patient populations.
Methods: PLATINUM SV and LL are prospective, single-arm, multinational studies
that enrolled patients with angina pectoris or documented silent ischemia and one de
novo native coronary artery target lesion. PLATINUM SV enrolled 94 subjects with
baseline vessel diameter 2.25mm to < 2.50mm and lesion length 28 mm, and
PLATINUM LL enrolled 102 patients with a target lesion >24 to 34mm long with
reference diameter 2.50 to 4.25mm.
Results: Patients were predominantly male (SV: 72.3%, LL: 62.7%) and approxi-
mately one third had diabetes (SV: 42.6%, LL: 30.0%). The mean baseline vessel
diameter in SV was 2.040.26 mm, and mean lesion length in LL was 24.388.21
mm. The primary endpoint, 1-year target lesion failure (TLF, deﬁned as cardiac
death or myocardial infarction related to the target vessel, or ischemia-driven target
lesion revascularization [TLR]), was 2.4% for SV and 3.2% for LL, which were
signiﬁcantly less than the prespeciﬁed performance goals of 21.1% for SV and
19.4% for LL (P< 0.001 for each). At 4 years, outcomes for 85 evaluable patients in
the SV trial were 6 (7.2%) TLFs, 3 (3.6%) TLRs, 4 (4.9%) cardiac deaths, 1 (1.1%)
noncardiac deaths, 2 (2.4%) MIs, and no ARC deﬁnite/probable ST events. Through
3-year follow-up in 95 evaluable LL patients, there were 11 (11.4%) TLFs, 6 (6.2%)
TLRs, 6 (6.3%) cardiac deaths, 1 (1.0%) non-cardiac death, and no MIs or ARC
deﬁnite/probable ST events. Four-year results for the LL study will be available at
the time of the meeting.
Conclusions: The PROMUS Element stent has demonstrated low TLF and revascu-
larization rates, and acceptable safety outcomes for the treatment of small vessels and
long lesions. The 4-year results from these studies will be available for presentation
for the ﬁrst time at TCT 2014.ronary Lesions - Long Lesions and Diffuse Disease B69
